The USFDA has concluded inspection (was conducted from 26th February 2018 to 1st March 2018) at the company's Unit II (formulation) with zero observations. Notably, LAURUS also has the Establishment Inspection Report (EIR) in place for the previous inspection that was conducted 15 months earlier. The company has cleared nine inspections successfully at its different facilities, indicating its consistency in regulatory compliance. It should, thus, face minimal regulatory hurdles over the medium term. This is commendable given that peers are facing regulatory hurdles to the extent that either existing business is stopped and/or new approvals have been halted by the USFDA